CLINICAL_TRIALS
trial_result
· 2010-03-02
Clinical Trial Update: Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma [Phase 2]
Summary
A Phase 2 study evaluating ipilimumab monotherapy in previously treated unresectable stage III or IV melanoma has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: COMPLETED